Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

21983 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-09-01

Study Completion Date

2018-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The HYGIA study was designed to investigate prospectively

1. the prognostic value of ambulatory blood pressure (BP) monitoring among subjects primarily evaluated at primary care settings
2. the impact of changes in ambulatory BP during follow-up in cardiovascular, cerebrovascular, metabolic, and renal risk in hypertensive patients
3. the influence of circadian time of treatment in cardiovascular, cerebrovascular, metabolic, and renal risk in hypertensive patients
4. the prevalence of an altered BP profile as a function of antihypertensive treatment, circadian time of treatment, age, and presence of diabetes, among other factors.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Treatment of Hypertension During Sleep

NCT03457168

Hypertension Hypertension, Systolic

RECRUITING NA

Ambulatory Blood Pressure Monitoring in the Prediction of Cardiovascular Events and Effects of Chronotherapy

NCT00295542

Hypertension

COMPLETED PHASE4

Knowledge of Vascular Age Contributes to Improve the Collaboration Between Community Pharmacies and Primary Health Care Physicians in Reducing Blood Pressure in Hypertensive Patients.

NCT06761235

Hypertension and Cardiovascular Risk Factors

NOT_YET_RECRUITING NA

Predictive Values of Blood Pressure and Arterial Stiffness in Institutionalized Very Aged Population

NCT00901355

Hypertension Elderly Cardiovascular Mortality +2 more

COMPLETED

Study of Maternal and Fetal Cardiovascular Function in Hypertensive States of Pregnancy

NCT06858345

Preeclampsia

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Ambulatory blood pressure (BP) measurements (ABPM) correlate more closely with target organ damage and cardiovascular events than clinical cuff measurements. ABPM reveals the significant circadian variation in BP, which in most individuals presents a morning increase, small post-prandial decline, and more extensive lowering during nocturnal rest. However, under certain pathophysiological conditions, the nocturnal BP decline may be reduced (non-dipper pattern) or even reversed (riser pattern). This is clinically relevant since the non-dipper and riser circadian BP patterns constitute a risk factor for left ventricular hypertrophy, albuminuria, cerebrovascular disease, congestive heart failure, vascular dementia, and myocardial infarction. Hence, there is growing interest in how to best tailor and individualize the treatment of hypertension according to the specific circadian BP pattern of each patient.

The reduction of the normal 10-20% sleep-time BP decline that is characteristic of the non-dipper and riser patterns is indeed associated with elevated risk of target organ damage, particularly to the heart (left ventricular hypertrophy, congestive heart failure, and myocardial infarction), brain (stroke), and kidney (albuminuria and progression to end-stage renal failure). These results suggest that cardiovascular risk could be influenced not by BP elevation alone, but also by the magnitude of the circadian BP variability. However, the potential dimension of an altered BP profile is still under debate, as there is current discrepancy on the actual prevalence of a non-dipper BP profile among groups of interest, mainly the elderly, patients with diabetes and patients with resistant hypertension.

Moreover, several independent prospective studies have suggested that nighttime BP may be a better predictor of cardiovascular risk than daytime BP. Common to all previous trials is that prognostic significance of ABPM has relied on a single baseline profile from each participant, without accounting for possible changes in the BP pattern, mainly associated to antihypertensive therapy and aging during follow-up. Moreover, the potential benefit, i.e., reduction in cardiovascular risk, associated with the normalization of the circadian BP variability (e.g., conversion from non-dipper to dipper pattern) from appropriately envisioned treatment strategy is still a matter of debate.

The HYGIA study was designed to investigate, first, the comparative prognostic value of several BP parameters (including, among many others, BP variability, the diurnal/nocturnal ratio, diurnal and nocturnal means, hyperbaric index, slope of morning rise, etc) in the prediction of vascular, metabolic, and renal morbidity and mortality; second, whether potential changes in the circadian BP pattern after treatment with hypertension medications may be associated to changes in the risk of cardiovascular events, stroke, diabetes, and/or chronic kidney disease; and third, in keeping with the second major objective above, to further assess the potential changes in efficacy, safety profile, and/or capability of hypertension medications, used either alone or in combination, to modulate the circadian BP pattern and to reduce vascular, metabolic, and renal risks as a function of the circadian time of administration.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Essential Hypertension Cardiovascular Disease Stroke Chronic Kidney Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Treatment with all prescribed hypertension medications on awakening

Group Type ACTIVE_COMPARATOR

Any antihypertensive medication alone or in combination

Intervention Type DRUG

All drugs on awakening

Ambulatory blood pressure monitoring

Intervention Type DEVICE

Sampling at 20-min intervals from 07:00 to 23:00 and at 30-min intervals at night for 48 consecutive hours

2

Treatment with at least one prescribed hypertension medication at bedtime

Group Type ACTIVE_COMPARATOR

Any antihypertensive medication alone or in combination

Intervention Type DRUG

One or more drugs at bedtime

Ambulatory blood pressure monitoring

Intervention Type DEVICE

Sampling at 20-min intervals from 07:00 to 23:00 and at 30-min intervals at night for 48 consecutive hours

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Any antihypertensive medication alone or in combination

All drugs on awakening

Intervention Type DRUG

Any antihypertensive medication alone or in combination

One or more drugs at bedtime

Intervention Type DRUG

Ambulatory blood pressure monitoring

Sampling at 20-min intervals from 07:00 to 23:00 and at 30-min intervals at night for 48 consecutive hours

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Olmesartan Irbesartan Candesartan Telmisartan Valsartan Atenolol Carvedilol Nevibolol Doxazosine Lercanidipine Manidipine Amlodipine Ramipril Enalapril Lisinopril Quinapril Olmesartan Irbesartan Candesartan Telmisartan Valsartan Atenolol Carvedilol Nevibolol Doxazosine Lercanidipine Manidipine Amlodipine Ramipril Enalapril Lisinopril Quinapril ABPM

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female subjects ≥18 years of age.
* High-normal BP or essential hypertension.
* Any subject with recommendation for evaluation with ABPM according to the 2007 European Guidelines.
* Informed consent to participate in the study prior to any study procedures.

Exclusion Criteria

* Known or suspected contraindications to any potential medication under investigation.
* Shift-workers.
* Inability to communicate and comply with all study requirements.
* Persons directly involved in the execution of this protocol.
* Intolerants to the use of the ABPM device.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes